Claims for Patent: 9,439,899

Summary for Patent: 9,439,899

Title:	Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
Abstract:	A pharmaceutical combination comprising a topoisomerase I inhibitor, and an Hsp90 inhibitor according to the following formulae (I) (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein. ##STR00001##
Inventor(s):	Proia; David (Newton, MA)
Assignee:	Synta Pharmaceuticals Corp. (Lexington, MA)
Application Number:	14/355,684
Patent Claims:	1. A pharmaceutical composition comprising a topoisomerase I inhibitor and an Hsp90 inhibitor wherein the topoisomerase I inhibitor is Irinotecan, topotecan, camptothecin, 9-aminocamptothecin, GG-211, DX-8951f and SN-38; and wherein the Hsp90 inhibitor is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1- ,2,4]triazole, 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-- 2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof. 2. The pharmaceutical composition of claim 1, wherein the Hsp90 inhibitor is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy- -[1,2,4]triazole or a tautomer or a pharmaceutically acceptable salt thereof. 3. The pharmaceutical composition of claim 1, wherein the Hsp90 inhibitor is 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-y- l)-2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof. 4. The pharmaceutical composition of claim 1, wherein the topoisomerase I inhibitor is irinotecan. 5. The pharmaceutical composition of claim 1, wherein the Hsp90 inhibitor is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy- -[1,2,4]triazole, or a tautomer or a pharmaceutically acceptable salt thereof, and the topoisomerase I inhibitor is irinotecan. 6. The pharmaceutical composition of claim 1, wherein the Hsp90 inhibitor is 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-y- l)-2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof, and the topoisomerase I inhibitor is irinotecan. 7. The pharmaceutical composition of claim 1, further comprising one or more additional therapeutic agents selected from the group consisting of vandetanib, trastuzumab, temodar, dexamethasone, cisplatin, epirubicin, ifosfamide, oxaliplatin, mitoxantrone, vorinostat, carboplatin, interferon alpha, rituxumab, prednisone, cyclophosphamide, bendamustine, adriamycin, valproate, celecoxib, thalidomide, nelarabine, methotrexate, filgrastim, gemtuzumab ozogamicin, testosterone, clofarabine, cytarabine, everolimus, busulfan, capecitabine, pegfilgrastim, mesna, amrubicin, obatoclax, gefitinib, cyclosporine, dasatinib, temozolomide, thiotepa, plerixafor, mitotane, vincristine, doxorubicin, cixutumumab, endostar, fenofibrate, melphalan, sunitinib, rubitecan, enoxaparin, isotretinoin, tariquidar, pomalidomide, sorafenib, altretamine, idarubicin, rapamycin, zevalin, pravastatin, carmustine, nelfinavir, streptozocin, tirapazamine, aprepitant, lenalidomide, G-CSF, procarbazine, alemtuzumab, amifostine, valspodar, lomustine, oblimersen, temsirolimus, vinblastine, figitumumab, belinostat, niacinamide, tipifarnib, estramustine, erlotinib, bevacizumab, paclitaxel, docetaxel, Abraxane.RTM., pemetrexed, bortezomib, cetuximab, gemcitabine, 5-fluorouracil, leucovorin and tetracycline. 8. The pharmaceutical composition of claim 7, wherein the one or more therapeutic agents is selected from the list consisting of carboplatin, cisplatin, erlotinib, bevacizumab, bortezomib, paclitaxel, doxorubicin, docetaxel, mitoxantrone, cytarabine, 5-fluorouracil, leucovorin and vincristine. 9. The pharmaceutical composition of claim 8, wherein the one or more additional agents are 5-fluorouracil and leucovorin. 10. A method of treating cancer in a subject, comprising administering to the subject an effective amount of an Hsp90 inhibitor and an effective amount of a topoisomerase I inhibitor, wherein the topoisomerase I inhibitor is Irinotecan, topotecan, camptothecin, 9-aminocamptothecin, GG-211, DX-8951f and SN-38; wherein the Hsp90 inhibitor is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1- ,2,4]triazole, 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-- 2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof; and wherein the cancer is colorectal cancer, ovarian cancer or non-small cell lung cancer. 11. The method of claim 10, wherein the cancer is colorectal cancer. 12. The method of claim 10, wherein irinotecan is administered at a dose of between about 100 mg/m.sup.2 to about 200 mg/m.sup.2; and the amount of the Hsp90 inhibitor is from about 2 mg/m.sup.2 to about 260 mg/m.sup.2. 13. The method of claim 12, wherein the amount of the Hsp90 inhibitor is about 75 mg/m.sup.2, about 85 mg/m.sup.2, about 100 mg/m.sup.2, about 110 mg/m.sup.2, about 115 mg/m.sup.2, about 120 mg/m.sup.2, about 145 mg/m.sup.2, about 150 mg/m.sup.2, about 175 mg/m.sup.2, about 180 mg/m.sup.2, about 200 mg/m.sup.2, about 215 mg/m.sup.2 or about 260 mg/m.sup.2. 14. The method of claim 10, wherein the Hsp90 inhibitor is administered IV once weekly or twice weekly. 15. A method of inhibiting the growth of a cancer or tumor cell in a subject, comprising the steps of: (a) contacting the cell with an effective amount of an Hsp90 inhibitor, wherein the Hsp90 inhibitor is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1- ,2,4]triazole, 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-- 2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof, and (b) exposing the cell to an effective amount of a topoisomerase I inhibitor, wherein the topoisomerase I inhibitor is selected from the group consisting of irinotecan, topotecan, camptothecin, 9-aminocamptothecin, GG-211, DX-8951f, and SN-38; and wherein the cancer is colorectal cancer, ovarian cancer or non-small cell lung cancer. 16. The method of claim 15, wherein the compound is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1- ,2,4]triazole, or a tautomer or a pharmaceutically acceptable salt thereof and the topoisomerase I inhibitor is irinotecan. 17. The method of claim 15, wherein the compound is 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-- 2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof, and the topoisomerase I inhibitor is irinotecan.

Details for Patent 9,439,899

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	02/20/1991		2031-11-02
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	06/28/2000		2031-11-02
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2031-11-02
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2031-11-02
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2031-11-02
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014		2031-11-02
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	10/12/2004		2031-11-02